Oppenheimer & CO Inc Vertex Pharmaceuticals Inc Transaction History

Oppenheimer & CO Inc

  • $6.52 Billion
  • Q4 2024

A detailed history of Oppenheimer & CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 7,629 shares of VRTX stock, worth $3.58 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
7,629
Previous 13,128 41.89%
Holding current value
$3.58 Million
Previous $6.11 Million 49.68%
% of portfolio
0.05%
Previous 0.1%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 04, 2025
SELL
$396.64 - $516.74 $2.18 Million - $2.84 Million
-5,499 Reduced 41.89%
7,629 $3.07 Million
Q3 2024

Nov 05, 2024
SELL
$460.0 - $505.78 $276,460 - $303,973
-601 Reduced 4.38%
13,128 $6.11 Million
Q2 2024

Aug 07, 2024
BUY
$392.81 - $485.53 $431,698 - $533,597
1,099 Added 8.7%
13,729 $6.44 Million
Q1 2024

May 06, 2024
BUY
$407.69 - $446.08 $307,398 - $336,344
754 Added 6.35%
12,630 $5.28 Million
Q4 2023

Feb 13, 2024
BUY
$343.0 - $410.68 $537,824 - $643,946
1,568 Added 15.21%
11,876 $4.83 Million
Q3 2023

Nov 07, 2023
BUY
$338.18 - $362.46 $607,709 - $651,340
1,797 Added 21.11%
10,308 $3.58 Million
Q2 2023

Aug 02, 2023
BUY
$314.42 - $351.91 $212,233 - $237,539
675 Added 8.61%
8,511 $3 Million
Q1 2023

May 10, 2023
SELL
$283.23 - $323.1 $2.14 Million - $2.44 Million
-7,563 Reduced 49.11%
7,836 $2.47 Million
Q4 2022

Feb 07, 2023
SELL
$285.76 - $321.48 $310,906 - $349,770
-1,088 Reduced 6.6%
15,399 $4.45 Million
Q3 2022

Nov 14, 2022
BUY
$273.83 - $305.53 $258,769 - $288,725
945 Added 6.08%
16,487 $4.77 Million
Q2 2022

Aug 08, 2022
BUY
$234.96 - $292.55 $228,381 - $284,358
972 Added 6.67%
15,542 $4.38 Million
Q1 2022

May 12, 2022
BUY
$221.42 - $260.97 $1.51 Million - $1.78 Million
6,805 Added 87.64%
14,570 $3.8 Million
Q4 2021

Feb 02, 2022
BUY
$177.01 - $223.45 $768,223 - $969,773
4,340 Added 126.72%
7,765 $1.71 Million
Q3 2021

Nov 12, 2021
BUY
$181.39 - $202.99 $243,788 - $272,818
1,344 Added 64.58%
3,425 $621,000
Q2 2021

Aug 03, 2021
SELL
$187.49 - $221.1 $553,845 - $653,129
-2,954 Reduced 58.67%
2,081 $420,000
Q1 2021

May 10, 2021
SELL
$207.02 - $241.31 $482,770 - $562,734
-2,332 Reduced 31.65%
5,035 $1.08 Million
Q4 2020

Feb 11, 2021
BUY
$207.01 - $276.09 $491,648 - $655,713
2,375 Added 47.58%
7,367 $1.74 Million
Q3 2020

Nov 13, 2020
SELL
$255.65 - $303.1 $948,972 - $1.13 Million
-3,712 Reduced 42.65%
4,992 $1.36 Million
Q2 2020

Aug 11, 2020
BUY
$225.48 - $295.8 $203,608 - $267,107
903 Added 11.58%
8,704 $2.53 Million
Q1 2020

May 08, 2020
BUY
$199.77 - $247.81 $462,068 - $573,184
2,313 Added 42.15%
7,801 $1.86 Million
Q4 2019

Feb 07, 2020
SELL
$166.71 - $223.91 $10,669 - $14,330
-64 Reduced 1.15%
5,488 $1.2 Million
Q3 2019

Oct 31, 2019
BUY
$166.23 - $187.09 $137,305 - $154,536
826 Added 17.48%
5,552 $941,000
Q2 2019

Aug 09, 2019
SELL
$164.61 - $190.37 $292,018 - $337,716
-1,774 Reduced 27.29%
4,726 $867,000
Q1 2019

Apr 24, 2019
SELL
$163.73 - $194.7 $215,304 - $256,030
-1,315 Reduced 16.83%
6,500 $1.2 Million
Q4 2018

Jan 29, 2019
SELL
$151.91 - $192.21 $560,092 - $708,678
-3,687 Reduced 32.06%
7,815 $1.3 Million
Q3 2018

Oct 26, 2018
BUY
$167.73 - $192.74 $553,844 - $636,427
3,302 Added 40.27%
11,502 $2.22 Million
Q2 2018

Aug 10, 2018
SELL
$145.72 - $169.96 $158,834 - $185,256
-1,090 Reduced 11.73%
8,200 $1.39 Million
Q1 2018

May 01, 2018
BUY
$151.6 - $177.13 $626,259 - $731,724
4,131 Added 80.07%
9,290 $1.51 Million
Q4 2017

Feb 07, 2018
BUY
$137.28 - $155.55 $98,017 - $111,062
714 Added 16.06%
5,159 $773,000
Q3 2017

Nov 09, 2017
BUY
$148.13 - $162.24 $658,437 - $721,156
4,445
4,445 $676,000

Others Institutions Holding VRTX

# of Institutions
1,718
Shares Held
221M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email